Interclean Shanghai

Egnite, Inc. Expands Technology to Improve the Quality of Care for Heart Failure Patients

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Advancing its application of artificial intelligence and data science to help improve patient care, egnite, Inc. expanded into heart failure for its flagship solution, CardioCare. This expansion leverages real-world insights to help physicians identify at-risk patients with heart failure and a reduced ejection fraction (HFrEF) who are not on guideline-directed medication and could benefit from timely intervention.

Early data from five heart programs managing more than 50,000 HFrEF patients indicate the 3-year survival rates for HFrEF patients prescribed 0 or 4 guideline-directed medications were 56% and 95% respectively. Thirty-day hospital readmissions for HFrEF patients prescribed 0 guideline-directed medications were three times higher than patients prescribed 4 medications, at 18% and 6% respectively.

These real-world insights from the CardioCare platform indicate an average of only 2.48% HFrEF patients are prescribed all 4 guideline-directed medications to manage their disease. “These data demonstrate significant opportunity to help improve survival and reduce readmission rates for heart failure patients,” said Joel Portice, chief executive officer, egnite. “CardioCare’s first to market technology helps hospital systems understand and improve the care for these large heart failure patent populations.”

Today, CardioCare is partnered with over 50 heart programs to reduce variability in care and improve guideline-directed treatment for patients with heart valve disease. This expansion into heart failure is the first of many for CardioCare as egnite continues its pursuit to elevate the standard of structural heart patient care by bringing leading-edge technologies to hospital systems.

“Healthcare information is moving rapidly with estimates of doubling five times a year. Data-driven population health initiatives like this are imperative to assist providers in managing their patients to the highest level of guideline-based care, the foundation of heart failure management. This work will improve patient management, quality of care, and save lives.” John Mignone, M.D., Ph.D., Robert M. and Patricia Arnold Endowed Medical Director for Heart Failure and Co-Executive Medical Director Swedish Heart and Vascular Institute.

 

 

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »